Indivior Pharmaceuticals (INDV) EBITDA Margin (2024 - 2026)

Indivior Pharmaceuticals' EBITDA Margin history runs 3 years deep, the most recent figure standing at 43.22% for Q1 2026.

• In Q1 2026, EBITDA Margin rose 2480.0% year-over-year to 43.22%; the TTM figure through Mar 2026 stood at 21.77% (up 1895.0% YoY), while the FY2025 annual figure was 21.15%, up 1795.0% from the prior year.
• EBITDA Margin was 43.22% for Q1 2026 at Indivior Pharmaceuticals, up from 22.63% in the prior quarter.
• In the past five years, EBITDA Margin ranged from a high of 43.22% in Q1 2026 to a low of 32.44% in Q2 2024.
• Historically, EBITDA Margin has averaged 13.3% across 3 years, with a median of 15.38% in 2024.
• Biggest YoY gain for EBITDA Margin was 3906 bps in 2025; the steepest drop was 235 bps in 2025.
• A 3-year view of EBITDA Margin shows it stood at 15.38% in 2024, then soared by 47 bps to 22.63% in 2025, then surged by 91 bps to 43.22% in 2026.
• The last three EBITDA Margin figures came in at 43.22% (Q1 2026), 22.63% (Q4 2025), and 13.69% (Q3 2025), per Business Quant data.